Letters to the Editor

ONF 2005, 32(4), 719-721. DOI: 10.1188/05.ONF.719-721

Jump to a section


    Bertelli, G., Gozza, G.B., Forno, M.G., Vidili, S., Silvestro, M., Venturini, L., et al. (1995). Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. Journal of Clinical Oncology, 113, 2851-2855.

    Brown, K.A., Esper, P., Kelleher, L.O., O'Neill, J.E.B., Polovich, M., & White, J.M. (2001). Chemotherapy and biotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society.

    Fox, M.E., & Smith, P.J. (1990). Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Research, 50, 5813-5818.

    Levin, M., Caravone, D., & Geiser, C. (1996). Mitoxantrone extravasation and tissue necrosis. American Journal of Health-System Pharmacy, 53, 1192, 1194.

    Peters, F.T., Beijnen, J.H., & ten Bokkel Huinink, W.W. (1987). Mitoxantrone extravasation injury. Cancer Treatment Reports, 71, 992-993.

    Serono, Inc. (2003). Novantrone® [Package insert]. Rockland, MA: Author. Retrieved February 6, 2005, from http://www.osip.com/OSI/images/docs/NovantronePI1-2003.pdf

    Tsavaris, N.B., Karagiaouris, P., Tzannou, I., Komitsopoulou, P., Bacoyiannis, C., Karabellis, A., et al. (1990). Conservative approach to the treatment of chemotherapy-induced extravasation. Journal of Dermatologic Surgery and Oncology, 16, 519-522.

    BayesMendel Lab. (2004). BRCAPRO. Retrieved June 2, 2005, from http://astor.som.jhmi.edu/BayesMendel/brcapro.html

    Euhus, D.M. (2001). Understanding mathematical models for breast cancer risk assessment and counseling. The Breast Journal, 7, 224-232.

    Euhus, D.M., Smith, K.C., Robinson, L., Stucky A., Olufunmilayo, I.O., Cummings, S., et al. (2002). Pretest prediction of BRCA1 orBRCA2 mutation by risk counselors and the computer model BRCAPRO. Journal of the National Cancer Institute, 94, 844-851.

    Mahon, S.M. (2003). Cancer risk assessment: Considerations for cancer genetics. In A.S. Tranin, A. Masny, & J. Jenkins (Eds.), Genetics in oncology practice: Cancer risk assessment (pp. 77-138). Pittsburgh, PA: Oncology Nursing Society.

    Berry, D.A., Iversen, E.S., Jr., Gudbjartsson, D.F., Hiller, E.H., Garber, J.E., Peshkin, B.N., et al. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology, 20, 2701-2712.

    Claus, E.B. (2001). Risk models used to counsel women for breast and ovarian cancer: A guide for clinicians. Familial Cancer, 1, 197-206.

    Couch, F.J., DeShano, M.L., Blackwood, M.A., Calzone, K., Stopfer, J., Campeau, L., et al. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New England Journal of Medicine, 336, 1409-1415.

    Domchek, S.M., Eisen, A., Calzone, K., Stopfer, J., Blackwood, A., & Weber, B.L. (2003). Application of breast cancer risk prediction models in clinical practice. Journal of Clinical Oncology, 21, 593-601.

    Frank, T.S., Manley, S.A., Olopade, O.I., Cummings, S., Garber, J.E., Bernhardt, B., et al. (1998). Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology, 16, 2417-2425.

    Hampel, H., Sweet, K., Westman, J.A., Offit, K., & Eng, C. (2004). Referral for cancer genetics consultation: aA review and compilation of risk assessment criteria. Journal of Medical Genetics, 41(2), 81-91.

    King, M.C., Marks, J.H., Mandell, J.B., & New York Breast Cancer Study Group. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643-646.

    Marroni, F., Aretini, P., D'Andrea, E., Caligo, M.A., Cortesi, L., Viel, A., et al. (2004). Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. Journal of Medical Genetics, 41, 278-285.

    National Comprehensive Cancer Network. (2003). Breast cancer risk reduction: Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 1, 280-296.

    Pichert, G., Bolliger, B., Buser, K., Pagani, O., & Swiss Institute for Applied Cancer Research Network for Cancer Predisposition Testing and Counseling. (2003). Evidence-based management options for women at increased breast/ovarian cancer risk. Annals of Oncology, 14, 9-19.

    Rubenstein, W.S., O'Neill, S.M., Peters, J.A., Rittmeyer, L.J., & Stadler, M.P. (2002). Mathematical modeling for breast cancer risk assessment—State of the art and role in medicine. Oncology, 16, 1082-1093.

    Sauven, P., & Association of Breast Surgery Family History Guidelines. (2004). Guidelines for the management of women at increased familial risk of breast cancer. European Journal of Cancer, 40, 653-665.

    Washburn, N.J., Sommer, V.K., Spencer, S.E., Simmons, S.K., Adkins, B.W., Rogers, M.R., et al. (2005). Outpatient genetic risk assessment in women with breast cancer: one center's experience. Clinical Journal of Oncology Nursing, 9, 49-53.